Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hansa Biopharma Ord Shs HNSBF

Healthcare Biotechnology
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G... see more

Recent & Breaking News (GREY:HNSBF)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

PR Newswire 2 days ago

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

PR Newswire May 21, 2024

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

PR Newswire December 14, 2023

Hansa Biopharma interim report January-March 2023

PR Newswire April 20, 2023

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

PR Newswire September 12, 2022

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform

PR Newswire July 18, 2022

The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022

PR Newswire May 30, 2022

Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

PR Newswire February 26, 2022

Hansa Biopharma provides business update including certain key financials

PR Newswire January 9, 2022

Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease

PR Newswire January 3, 2022

Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update

PR Newswire July 1, 2021

Hansa Biopharma publishes Annual Report 2020

PR Newswire April 8, 2021

Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development

PR Newswire March 1, 2021

Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update

PR Newswire January 27, 2021

Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference

PR Newswire December 23, 2020

Hansa Biopharma Nomination Committee formed

PR Newswire November 2, 2020

Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen

PR Newswire September 17, 2020

Hansa Biopharma Interim Report Jan-Jun 2020

PR Newswire July 16, 2020

Hansa Biopharma Submits Responses to Outstanding Questions From EMA on May 26

PR Newswire May 25, 2020

Hansa Biopharma to Participate in Five Upcoming Investor Conferences During May and June

PR Newswire May 13, 2020